Laboratory Corporation of America Holdings (LH) Shares are Down -1.46%

Laboratory Corporation of America Holdings (LH) : During the past 4 weeks, traders have been relatively bearish on Laboratory Corporation of America Holdings (LH), hence the stock is down -2.32% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.8% relative to the S&P 500. The 4-week change in the price of the stock is -2.52% and the stock has fallen -1.46% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 2.2% and the fifty day Moving Average is 0.41%. Laboratory Corp. of America Holdings is up 6.27% in the last three month period. Year-to-Date the stock performance stands at 10.03%.

Laboratory Corporation of America Holdings (LH) : The highest short term price target forecast on Laboratory Corporation of America Holdings (LH) is $160 and the lowest target price is $132. A total of 13 equity analysts are currently covering the company. The average price of all the analysts is $148.42 with a standard deviation of $9.42.


Laboratory Corporation of America Holdings (NYSE:LH): stock turned positive on Friday. Though the stock opened at $135.41, the bulls momentum made the stock top out at $137.23 level for the day. The stock recorded a low of $135.21 and closed the trading day at $136.04, in the green by 0.46%. The total traded volume for the day was 781,234. The stock had closed at $135.42 in the previous days trading.

Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment, which includes core testing, as well as genomic and esoteric testing; and the Other segment, which consists of the Companys non-United States clinical diagnostic laboratory operations in Ontario, Canada. It also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, womens health, cardiovascular disease, identity, forensics, infectious disease, endocrinology, oncology, coagulation, occupational testing and pain management.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.